AAAAAA
Results:
1-11
|
Results: 11
Authors:
Chiaffarino, F
Parazzini, F
Negri, E
Benzi, G
Scarfone, G
Franceschi, S
La Vecchia, C
Citation: F. Chiaffarino et al., Time since last birth and the risk of ovarian cancer, GYNECOL ONC, 81(2), 2001, pp. 233-236
Authors:
Bolis, G
Scarfone, G
Villa, A
Parazzini, F
Citation: G. Bolis et al., Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer, GYNECOL ONC, 81(2), 2001, pp. 331-333
Authors:
Bolis, G
Scarfone, G
Giardina, G
Villa, A
Mangili, G
Melpignano, M
Presti, M
Tateo, S
Franchi, M
Parazzini, F
Citation: G. Bolis et al., Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer, GYNECOL ONC, 81(1), 2001, pp. 3-9
Authors:
Bolis, G
Scarfone, G
Tateo, S
Mangili, G
Villa, A
Parazzini, F
Citation: G. Bolis et al., Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel, GYNECOL ONC, 80(1), 2001, pp. 13-15
Authors:
Vercellini, P
Scarfone, G
Bolis, G
Stellato, G
Carinelli, S
Crosignani, PG
Citation: P. Vercellini et al., Site of origin of epithelial ovarian cancer: the endometriosis connection, BR J OBST G, 107(9), 2000, pp. 1155-1157
Authors:
Ruggeri, B
Ballatori, E
Roila, F
De Angelis, V
Tonato, M
Del Favero, A
Ciccarese, G
Basurto, C
Ciccarese, G
Palladino, MA
Porrozzi, S
Picciafuoco, M
Contu, SA
Olmeo, N
Pazzola, A
Pilo, L
Tateo, PS
Salamano, S
Morana, S
Lucchino, S
Ricci, S
Antonuzzo, A
Allegrini, G
Galli, L
Conte, PF
Massidda, B
Ionta, MT
Scanu, A
Murru, R
Picece, V
Nicodemo, M
Recaldin, E
Nuzzo, A
Laudadio, L
D'Ostilio, N
Locatelli, MC
D'Antona, A
Luporini, G
Scagliotti, G
Selvaggi, G
Mattei, A
Favalli, G
Gambino, A
Fava, S
Grimi, E
Fava, S
Grimi, E
Scarfone, G
Bolis, MC
Alessandroni, P
Catalano, G
Boni, C
Moretti, G
Cortesi, E
Martelli, O
Antimi, M
Bellini, V
Buzzi, F
Brugia, M
Grecchi, G
Clerico, M
Montinari, F
Donati, D
Sansoni, E
Citation: B. Ruggeri et al., Prevention of cisplatin-induced delayed emesis: still unsatisfactory, SUPP CARE C, 8(3), 2000, pp. 229-232
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
Authors:
Lavarino, C
Pilotti, S
Oggionni, M
Gatti, L
Perego, P
Bresciani, G
Pierotti, MA
Scambia, G
Ferrandina, G
Fagotti, A
Mangioni, C
Lucchini, V
Vecchione, F
Bolis, G
Scarfone, G
Zunino, F
Citation: C. Lavarino et al., p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma, J CL ONCOL, 18(23), 2000, pp. 3936-3945
Authors:
Scarfone, G
Citation: G. Scarfone, Topoteca: Possible use in combination therapy for ovarian cancer, TUMORI, 85(6), 1999, pp. S12-S15
Authors:
Scarfone, G
Villa, A
Parazzini, F
Sciatta, C
Polverino, G
Bolis, G
Citation: G. Scarfone et al., A phase I-II trial of high-dose ifosfamide in patients with ovarian cancerrefractory or resistant to platinum and/or paclitaxel-containing chemotherapy, TUMORI, 85(4), 1999, pp. 217-219
Authors:
Bolis, G
Parazzini, F
Scarfone, G
Villa, A
Amoroso, M
Rabaiotti, E
Polatti, A
Reina, S
Pirletti, E
Citation: G. Bolis et al., Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer, GYNECOL ONC, 72(1), 1999, pp. 60-64
Authors:
Villa, A
Parazzini, F
Scarfone, G
Guarnerio, P
Bolis, G
Citation: A. Villa et al., Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients, BR J CANC, 79(2), 1999, pp. 373-374
Risultati:
1-11
|